Big Pharma is using dark money to fund groups that sound like patient advocacy organizations but represent the industry.

Roche's Genentech is sticking with Orionis Biosciences, handing over $105 million upfront as part of its second deal with the ...

Eli Lilly is to buy the private biotech Disarm Therapeutics, which is working on a new class of disease-modifying drugs for neurological diseases, in a deal worth up to $1.36 billion.

Eli Lilly's gene-silencing drug lepodisiran has ... inhibitor from China's Jiangsu Hengrui Pharma for $200m upfront.